Skip to content

13F-HR filed by NOVO HOLDINGS A/S

NOVO HOLDINGS A/S filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-15, with 31 holding rows worth $1,314,623,581.

Accession
0000950123-25-005753
Filed
2025-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2025

A holdings report, 31 entries on the cover page, a total value of $1,314,623,581 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,314,623,581 with VALUE read as dollars as filed, 13F file number 028-16231. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
VTI922908769COM1,038,550$285,435,082dollars as filed
BROOKFIELD CORP CL A LTD VT SH11271J107Stock2,330,830$122,158,800dollars as filed
EDGEWISE THERAPEUTICS INC28036F105COM5,350,000$117,700,000dollars as filed
ASMLHLDGNVFSPONSOREDADR1ADRREPS1ORDSHSN07059210STOK165,836$109,887,909dollars as filed
Salesforce.com, Inc79466L302COM272,801$73,208,876dollars as filed
MIRUM PHARMACEUTICALS INC604749101COM1,500,000$67,575,000dollars as filed
INSMED INC COM PAR $.01457669307Stock724,666$55,284,769dollars as filed
RECURSION PHARMACEUTICALS IN75629V104CL A9,665,128$51,128,527dollars as filed
ALIBABA GROUP HLDG LTD01609W102SPONSORED ADS372,327$49,232,799dollars as filed
CRINETICS PHARMACEUTICALS INC COM22663K107Stock1,275,000$42,763,500dollars as filed
BIOMARIN PHARMACEUTICAL INC09061G101COM490,000$34,638,100dollars as filed
ARRIVENT BIOPHARMA INC04272N102COM1,872,142$34,615,906dollars as filed
VAXCYTE INC COM92243G108Stock915,000$34,550,400dollars as filed
MERUS N VN5749R100COM789,129$33,214,440dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM2,250,300$30,334,044dollars as filed
PHARVARIS NVN69605108COMMON STOCK1,725,000$27,082,500dollars as filed
AMICUS THERAPEUTICS INC03152W109COM2,750,000$22,440,000dollars as filed
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW1,200,000$21,780,000dollars as filed
BLUEPRINT MEDICINES CORP09627Y109COM228,804$20,251,442dollars as filed
ZENAS BIOPHARMA INC COM98937L105Stock2,214,967$17,498,239dollars as filed
CERIBELL INC15678C102COMMON STOCK880,000$16,904,800dollars as filed
VERVE THERAPEUTICS INC92539P101COM3,000,000$13,710,000dollars as filed
ROCKET PHARMACEUTICALS INC77313F106COM1,100,000$7,337,000dollars as filed
4D MOLECULAR THERAPEUTICS INC COM35104E100Stock1,950,000$6,298,500dollars as filed
LEXEO THERAPEUTICS INC52886X107COMMON STOCK1,122,581$3,895,356dollars as filed
LANZATECH GLOBAL INC51655R101COM15,814,845$3,828,774dollars as filed
IO BIOTECH INC449778109COM3,354,449$3,656,349dollars as filed
KYVERNA THERAPEUTICS INC501976104COMMON STOCK1,850,000$3,570,500dollars as filed
ABCELLERA BIOLOGICS INC COM00288U106Stock1,126,915$2,513,020dollars as filed
MARQETA INC57142B104CLASS A COM441,558$1,819,219dollars as filed
DAMORA THERAPEUTICS INC36322Q206COMMON STOCK99,913$309,730dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-25-005753this filing2025-05-15acceptance time not in the bulk data set